Monopar Therapeutics Inc.

NasdaqCM:MNPR Stock Report

Market Cap: US$12.7m

Monopar Therapeutics Management

Management criteria checks 2/4

Monopar Therapeutics' CEO is Chandler Robinson, appointed in Dec 2014, has a tenure of 9.42 years. total yearly compensation is $1.78M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth $120.81K. The average tenure of the management team and the board of directors is 8.2 years and 8.3 years respectively.

Key information

Chandler Robinson

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage32.6%
CEO tenure9.4yrs
CEO ownership1.0%
Management average tenure8.2yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Mar 02
Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nov 16
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Oct 05

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Jul 30
We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Mar 28
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Jul 15
We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar nabs U.S. patent covering camsirubicin

Dec 22

Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19

Dec 10

Monopar launches validive mid-stage study in chemo-induced oral mucositis

Dec 08

Monopar Therapeutics EPS beats by $0.02

Nov 12

CEO Compensation Analysis

How has Chandler Robinson's remuneration changed compared to Monopar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$580k

-US$8m

Sep 30 2023n/an/a

-US$9m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$2mUS$550k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$10m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$1mUS$525k

-US$9m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$2mUS$504k

-US$6m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019US$541kUS$386k

-US$4m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$1mUS$375k

-US$3m

Sep 30 2018n/an/a

-US$3m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017US$401kUS$331k

-US$17m

Compensation vs Market: Chandler's total compensation ($USD1.78M) is above average for companies of similar size in the US market ($USD663.90K).

Compensation vs Earnings: Chandler's compensation has increased whilst the company is unprofitable.

CEO

Chandler Robinson (39 yo)

9.4yrs

Tenure

US$1,778,655

Compensation

Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...

Leadership Team

NamePositionTenureCompensationOwnership
Chandler Robinson
Co-Founder9.4yrsUS$1.78m0.95%
$ 120.8k
Kim Tsuchimoto
CFO, Secretary8.9yrsUS$848.44k0.29%
$ 36.7k
Andrew Cittadine
Chief Operating Officer2.9yrsUS$911.14k0.33%
$ 41.9k
Patrice Rioux
Acting Chief Medical Officer7.4yrsno datano data

8.2yrs

Average Tenure

55yo

Average Age

Experienced Management: MNPR's management team is seasoned and experienced (8.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chandler Robinson
Co-Founder9.4yrsUS$1.78m0.95%
$ 120.8k
Kim Tsuchimoto
CFO, Secretary1.2yrsUS$848.44k0.29%
$ 36.7k
Michael Brown
Independent Director9.4yrsUS$126.04k1.35%
$ 171.5k
Raymond Anderson
Independent Director7.1yrsUS$136.54k0.15%
$ 19.5k
Christopher Starr
Independent Executive Chairman of the Board9.4yrsUS$264.04k0.43%
$ 54.7k
Arthur Klausner
Independent Director6.8yrsUS$128.54k0.18%
$ 22.4k

8.3yrs

Average Tenure

64.5yo

Average Age

Experienced Board: MNPR's board of directors are considered experienced (8.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.